Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Neutralizing Antibody-Mediated Response and Risk of BK Virus-Associated Nephropathy.

Solis M, Velay A, Porcher R, Domingo-Calap P, Soulier E, Joly M, Meddeb M, Kack-Kack W, Moulin B, Bahram S, Stoll-Keller F, Barth H, Caillard S, Fafi-Kremer S.

J Am Soc Nephrol. 2018 Jan;29(1):326-334. doi: 10.1681/ASN.2017050532. Epub 2017 Oct 17.

PMID:
29042457
2.

Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma.

Le Guillou-Guillemette H, Pivert A, Bouthry E, Henquell C, Petsaris O, Ducancelle A, Veillon P, Vallet S, Alain S, Thibault V, Abravanel F, Rosenberg AA, André-Garnier E, Bour JB, Baazia Y, Trimoulet P, André P, Gaudy-Graffin C, Bettinger D, Larrat S, Signori-Schmuck A, Saoudin H, Pozzetto B, Lagathu G, Minjolle-Cha S, Stoll-Keller F, Pawlotsky JM, Izopet J, Payan C, Lunel-Fabiani F, Lemaire C.

PLoS One. 2017 Apr 10;12(4):e0174651. doi: 10.1371/journal.pone.0174651. eCollection 2017.

3.

Problem-based learning in laboratory medicine resident education: a satisfaction survey.

Lepiller Q, Solis M, Velay A, Gantner P, Sueur C, Stoll-Keller F, Barth H, Fafi-Kremer S.

Ann Biol Clin (Paris). 2017 Apr 1;75(2):181-192. doi: 10.1684/abc.2017.1236.

PMID:
28377331
4.

45 years after the discovery of human polyomaviruses BK and JC: Time to speed up the understanding of associated diseases and treatment approaches.

Barth H, Solis M, Lepiller Q, Sueur C, Soulier E, Caillard S, Stoll-Keller F, Fafi-Kremer S.

Crit Rev Microbiol. 2017 Mar;43(2):178-195. doi: 10.1080/1040841X.2016.1189873. Epub 2016 Nov 1. Review.

PMID:
27800693
5.

Long-term storage and safe retrieval of human papillomavirus DNA using FTA elute cards.

Barth H, Morel A, Mougin C, Averous G, Legrain M, Fender M, Risch S, Fafi-Kremer S, Velten M, Oudet P, Baldauf JJ, Stoll-Keller F.

J Virol Methods. 2016 Mar;229:60-5. doi: 10.1016/j.jviromet.2015.12.010. Epub 2015 Dec 23.

PMID:
26721377
6.

Sequence Variation in Amplification Target Genes and Standards Influences Interlaboratory Comparison of BK Virus DNA Load Measurement.

Solis M, Meddeb M, Sueur C, Domingo-Calap P, Soulier E, Chabaud A, Perrin P, Moulin B, Bahram S, Stoll-Keller F, Caillard S, Barth H, Fafi-Kremer S; French BKV Study Group.

J Clin Microbiol. 2015 Dec;53(12):3842-52. doi: 10.1128/JCM.02145-15. Epub 2015 Oct 14.

7.

Influenza prevention in nursing homes: Great significance of seasonal variability and spatio-temporal pattern.

Gaspard P, Mosnier A, Stoll-Keller F, Roth C, Larocca S, Bertrand X.

Presse Med. 2015 Oct;44(10):e311-9. doi: 10.1016/j.lpm.2015.04.041.

PMID:
26433834
8.

Ten influenza seasons in France: distribution and timing of influenza A and B circulation, 2003-2013.

Mosnier A, Caini S, Daviaud I, Bensoussan JL, Stoll-Keller F, Bui TT, Lina B, Van der Werf S, Cohen JM; GROG network.

BMC Infect Dis. 2015 Aug 21;15:357. doi: 10.1186/s12879-015-1056-z.

9.

Identification of a duplicated V3 domain in NS5A associated with cirrhosis and hepatocellular carcinoma in HCV-1b patients.

Le Guillou-Guillemette H, Ducancelle A, Bertrais S, Lemaire C, Pivert A, Veillon P, Bouthry E, Alain S, Thibault V, Abravanel F, Rosenberg AR, Henquell C, André-Garnier E, Petsaris O, Vallet S, Bour JB, Baazia Y, Trimoulet P, André P, Gaudy-Graffin C, Bettinger D, Larrat S, Signori-Schmuck A, Saoudin H, Pozzetto B, Lagathu G, Minjolle-Cha S, Stoll-Keller F, Pawlotsky JM, Izopet J, Payan C, Lunel-Fabiani F.

J Clin Virol. 2015 Aug;69:203-9. doi: 10.1016/j.jcv.2015.06.096. Epub 2015 Jun 24.

10.

[Clinical laboratory medicine: continuous amelioration with a book of objectives and satisfaction survey].

Reix N, Agin A, Bahram S, Dali-Youcef N, Grucker D, Jaulhac B, Lepiller Q, Lessinger JM, Mauvieux L, Monier L, Schramm F, Stoll-Keller F, Vallat L, Ludes B, Candolfi E, Filisetti D.

Ann Biol Clin (Paris). 2015 May-Jun;73(3):359-68. doi: 10.1684/abc.2015.1045. French.

PMID:
25869036
11.

Antiviral and Immunoregulatory Effects of Indoleamine-2,3-Dioxygenase in Hepatitis C Virus Infection.

Lepiller Q, Soulier E, Li Q, Lambotin M, Barths J, Fuchs D, Stoll-Keller F, Liang TJ, Barth H.

J Innate Immun. 2015;7(5):530-44. doi: 10.1159/000375161. Epub 2015 Mar 19.

12.

Clinical relevance of herpes simplex virus viremia in Intensive Care Unit patients.

Lepiller Q, Sueur C, Solis M, Barth H, Glady L, Lefebvre F, Fafi-Kremer S, Schneider F, Stoll-Keller F.

J Infect. 2015 Jul;71(1):93-100. doi: 10.1016/j.jinf.2015.02.013. Epub 2015 Mar 4.

PMID:
25749257
13.

Toward standardization of BK virus monitoring: evaluation of the BK virus R-gene kit for quantification of BK viral load in urine, whole-blood, and plasma specimens.

Sueur C, Solis M, Meddeb M, Soulier E, Domingo-Calap P, Lepiller Q, Freitag R, Bahram S, Caillard S, Barth H, Stoll-Keller F, Fafi-Kremer S.

J Clin Microbiol. 2014 Dec;52(12):4298-304. doi: 10.1128/JCM.02031-14. Epub 2014 Oct 8.

14.

Influenza outbreaks management in a French psychiatric hospital from 2004 to 2012.

Gaspard P, Mosnier A, Gunther D, Lochert C, Larocca S, Minery P, Stoll-Keller F, Bertrand X, Talon D.

Gen Hosp Psychiatry. 2014 Jan-Feb;36(1):46-52. doi: 10.1016/j.genhosppsych.2013.01.009. Epub 2013 Oct 2.

PMID:
24095038
15.

High incidence but low burden of coronaviruses and preferential associations between respiratory viruses.

Lepiller Q, Barth H, Lefebvre F, Herbrecht R, Lutz P, Kessler R, Fafi-Kremer S, Stoll-Keller F.

J Clin Microbiol. 2013 Sep;51(9):3039-46. doi: 10.1128/JCM.01078-13. Epub 2013 Jul 12.

16.

Genotype 1 hepatitis C virus envelope features that determine antiviral response assessed through optimal covariance networks.

Murray JM, Moenne-Loccoz R, Velay A, Habersetzer F, Doffoël M, Gut JP, Fofana I, Zeisel MB, Stoll-Keller F, Baumert TF, Schvoerer E.

PLoS One. 2013 Jun 20;8(6):e67254. doi: 10.1371/journal.pone.0067254. Print 2013.

17.

Hepatitis C virus vaccines--progress and perspectives.

Fauvelle C, Lepiller Q, Felmlee DJ, Fofana I, Habersetzer F, Stoll-Keller F, Baumert TF, Fafi-Kremer S.

Microb Pathog. 2013 May;58:66-72. doi: 10.1016/j.micpath.2013.02.005. Epub 2013 Mar 7. Review.

PMID:
23499591
18.

Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization.

Schvoerer E, Moenne-Loccoz R, Murray JM, Velay A, Turek M, Fofana I, Fafi-Kremer S, Erba AC, Habersetzer F, Doffoël M, Gut JP, Donlin MJ, Tavis JE, Zeisel MB, Stoll-Keller F, Baumert TF.

J Infect Dis. 2013 Apr 15;207(8):1306-15. doi: 10.1093/infdis/jit032. Epub 2013 Jan 18.

PMID:
23335805
19.

Neutralizing antibodies and pathogenesis of hepatitis C virus infection.

Fafi-Kremer S, Fauvelle C, Felmlee DJ, Zeisel MB, Lepiller Q, Fofana I, Heydmann L, Stoll-Keller F, Baumert TF.

Viruses. 2012 Oct 9;4(10):2016-30. doi: 10.3390/v4102016. Review.

20.

Challenges for HCV vaccine development in HIV-HCV coinfection.

Lambotin M, Barth H, Moog C, Habersetzer F, Baumert TF, Stoll-Keller F, Fafi-Kremer S.

Expert Rev Vaccines. 2012 Jul;11(7):791-804. doi: 10.1586/erv.12.52. Review.

PMID:
22913257
21.

Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies.

Fofana I, Fafi-Kremer S, Carolla P, Fauvelle C, Zahid MN, Turek M, Heydmann L, Cury K, Hayer J, Combet C, Cosset FL, Pietschmann T, Hiet MS, Bartenschlager R, Habersetzer F, Doffoël M, Keck ZY, Foung SKH, Zeisel MB, Stoll-Keller F, Baumert TF.

Gastroenterology. 2012 Jul;143(1):223-233.e9. doi: 10.1053/j.gastro.2012.04.006. Epub 2012 Apr 10.

22.

Circulation of genotype 4 hepatitis E virus in Europe: first autochthonous hepatitis E infection in France.

Tessé S, Lioure B, Fornecker L, Wendling MJ, Stoll-Keller F, Bigaillon C, Nicand E.

J Clin Virol. 2012 Jun;54(2):197-200. doi: 10.1016/j.jcv.2012.02.007. Epub 2012 Mar 10.

PMID:
22405947
23.

Parvovirus B19-induced type II mixed cryoglobulinemia.

Gorse A, Boileau J, Goetz J, Stoll-Keller F, Martin T.

Am J Med. 2011 Sep;124(9):e7-8. doi: 10.1016/j.amjmed.2011.02.039. No abstract available.

PMID:
21854885
24.

[Clusters of respiratory tract infections and alert strategy in nursing homes].

Gaspard P, Mosnier A, Cohen JM, Gunther D, Roth C, Stoll-Keller F, Gayet S, Bertrand X, Talon D; Les référents GROG Géronto-Alsace.

Med Mal Infect. 2011 May;41(5):253-61. doi: 10.1016/j.medmal.2010.12.008. Epub 2011 Jan 28. French.

PMID:
21277131
25.

Interpretation of real-time PCR results for hepatitis C virus RNA when viral load is below quantification limits.

Laperche S, Bouchardeau F, André-Garnier E, Thibault V, Roque-Afonso AM, Trimoulet P, Colimon R, Duverlie G, Leguillou-Guillemette H, Lunel F, Bouvier-Alias M, Pawlotsky JM, Henquell C, Schvoerer E, Stoll-Keller F, Chaix ML, Branger M, Gaudy-Graffin C, Rosenberg AR, Pozzetto B, Vallet S, Baazia Y, Izopet J, Lefrère JJ.

J Clin Microbiol. 2011 Mar;49(3):1113-5. doi: 10.1128/JCM.01511-10. Epub 2011 Jan 12.

26.

Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation.

Fafi-Kremer S, Fofana I, Soulier E, Carolla P, Meuleman P, Leroux-Roels G, Patel AH, Cosset FL, Pessaux P, Doffoël M, Wolf P, Stoll-Keller F, Baumert TF.

J Exp Med. 2010 Aug 30;207(9):2019-31. doi: 10.1084/jem.20090766. Epub 2010 Aug 16.

27.

Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.

Fofana I, Krieger SE, Grunert F, Glauben S, Xiao F, Fafi-Kremer S, Soulier E, Royer C, Thumann C, Mee CJ, McKeating JA, Dragic T, Pessaux P, Stoll-Keller F, Schuster C, Thompson J, Baumert TF.

Gastroenterology. 2010 Sep;139(3):953-64, 964.e1-4. doi: 10.1053/j.gastro.2010.05.073. Epub 2010 Jun 2.

28.

Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies.

Georgel P, Schuster C, Zeisel MB, Stoll-Keller F, Berg T, Bahram S, Baumert TF.

Trends Mol Med. 2010 Jun;16(6):277-86. doi: 10.1016/j.molmed.2010.04.003. Epub 2010 May 25. Review.

PMID:
20537953
29.

A look behind closed doors: interaction of persistent viruses with dendritic cells.

Lambotin M, Raghuraman S, Stoll-Keller F, Baumert TF, Barth H.

Nat Rev Microbiol. 2010 May;8(5):350-60. doi: 10.1038/nrmicro2332. Epub 2010 Apr 7. Review.

30.

EBV limbic encephalitis after allogenic hematopoietic stem cell transplantation.

Kremer S, Matern JF, Bilger K, Lioure B, Fornecker Y, Stoll-Keller F, Namer IJ, Dietemann JL, Fafi-Kremer S.

J Neuroradiol. 2010 Jul;37(3):189-91. doi: 10.1016/j.neurad.2009.10.001. Epub 2009 Dec 2.

31.

[Tropism of hepatitis C virus for leukocytes-- importance of the analysis of viral E1 and E2 envelope glycoprotein genes by sequencing].

Moenne-Loccoz R, Razafinjatovo C, Habersetzer F, Ananna A, Doffoel M, Wolf P, Gut JP, Baumert T, Stoll-Keller F, Schvoerer E.

Pathol Biol (Paris). 2010 Apr;58(2):170-4. doi: 10.1016/j.patbio.2009.06.010. Epub 2009 Nov 4. Review. French.

PMID:
19892492
32.

Adaptive immunity to hepatitis C virus.

Zeisel MB, Fafi-Kremer S, Robinet E, Habersetzer F, Baumert TF, Stoll-Keller F.

Viruses. 2009 Sep;1(2):276-97. doi: 10.3390/v1020276. Epub 2009 Sep 8.

33.

GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection.

Habersetzer F, Baumert TF, Stoll-Keller F.

Curr Opin Mol Ther. 2009 Aug;11(4):456-62.

PMID:
19649991
34.

[Novel strategies for preventing viral hepatitis C recurrence after liver transplantation].

Stoll-Keller F, Fafi-Kremer S, Wolf P, Doffoël M, Baumert T.

Bull Acad Natl Med. 2008 Nov;192(8):1657-67; discussion 1667-8. Review. French. Erratum in: Bull Acad Natl Med. 2009 Jun;193(6):1359-60.

PMID:
19445379
35.

Development of hepatitis C virus vaccines: challenges and progress.

Stoll-Keller F, Barth H, Fafi-Kremer S, Zeisel MB, Baumert TF.

Expert Rev Vaccines. 2009 Mar;8(3):333-45. doi: 10.1586/14760584.8.3.333. Review.

36.

Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients.

Pastor R, Habersetzer F, Fafi-Kremer S, Doffoel M, Baumert TF, Gut JP, Stoll-Keller F, Schvoerer E.

World J Gastroenterol. 2009 Feb 14;15(6):753-5.

37.

Toll-like receptor 2 senses hepatitis C virus core protein but not infectious viral particles.

Hoffmann M, Zeisel MB, Jilg N, Paranhos-Baccalà G, Stoll-Keller F, Wakita T, Hafkemeyer P, Blum HE, Barth H, Henneke P, Baumert TF.

J Innate Immun. 2009;1(5):446-54. doi: 10.1159/000226136. Epub 2009 Jun 23.

38.

Frequent compartmentalization of hepatitis C virus with leukocyte-related amino acids in the setting of liver transplantation.

Schramm F, Soulier E, Royer C, Weitten T, Fafi-Kremer S, Brignon N, Meyer N, Ellero B, Woehl-Jaegle ML, Meyer C, Wolf P, Doffoël M, Baumert TF, Stoll-Keller F, Schvoerer E.

J Infect Dis. 2008 Dec 1;198(11):1656-66. doi: 10.1086/592986.

PMID:
18925843
39.

[Study of hepatitis C virus leukotropism by characterization of viral quasispecies in the liver transplantation setting].

Schramm F, Moenne-Loccoz R, Fafi-Kremer S, Soulier E, Royer C, Weitten T, Brignon N, Ellero B, Woehl-Jaegle ML, Meyer C, Wolf P, Doffoel M, Baumert TF, Gut JP, Stoll-Keller F, Schvoerer E.

Pathol Biol (Paris). 2008 Nov-Dec;56(7-8):487-91. doi: 10.1016/j.patbio.2008.07.007. Epub 2008 Oct 7. Review. French.

PMID:
18842359
40.

[Immunoassay rapid test for influenza diagnosis in institutions for elderly people: a four-year surveillance with the GROG Géronto-Alsace].

Gaspard P, Mosnier A, Cohen JM, Gunther D, Roth C, Eschbach E, Stoll-Keller F, Gayet S; GROG Géronto-Alsace.

Pathol Biol (Paris). 2009 Feb;57(1):90-6. doi: 10.1016/j.patbio.2008.08.007. Epub 2008 Oct 2. French.

PMID:
18835108
41.

Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion.

Haberstroh A, Schnober EK, Zeisel MB, Carolla P, Barth H, Blum HE, Cosset FL, Koutsoudakis G, Bartenschlager R, Union A, Depla E, Owsianka A, Patel AH, Schuster C, Stoll-Keller F, Doffoël M, Dreux M, Baumert TF.

Gastroenterology. 2008 Nov;135(5):1719-1728.e1. doi: 10.1053/j.gastro.2008.07.018. Epub 2008 Jul 22.

PMID:
18718838
42.

[Neutralizing antibodies in hepatitis C virus infection].

Fafi-Kremer S, Zeisel MB, Schvoerer E, Soulier E, Habersetzer F, Wolf P, Doffoel M, Baumert TF, Stoll-Keller F.

Gastroenterol Clin Biol. 2008 May;32(5 Pt 1):491-8. doi: 10.1016/j.gcb.2008.02.026. Epub 2008 May 7. Review. French.

43.

Efficient postexposure prophylaxis by hepatitis A vaccine.

Fafi-Kremer S, Stoll-Keller F, Baumert TF.

Hepatology. 2008 Apr;47(4):1416-8. doi: 10.1002/hep.22274. No abstract available.

PMID:
18366112
44.

Hepatitis C virus structural proteins do not prevent human dendritic cell maturation.

Thumann C, Schvoerer E, Abraham JD, Bohbot A, Stoll-Keller F, Aubertin AM, Kieny MP.

Gastroenterol Clin Biol. 2008 Jan;32(1 Pt. 1):59-68. doi: 10.1016/j.gcb.2007.12.006. Epub 2008 Mar 4.

45.

Association of interleukin-18 polymorphisms and plasma level with the outcome of chronic HCV infection.

Bouzgarrou N, Hassen E, Schvoerer E, Stoll-Keller F, Bahri O, Gabbouj S, Cheikh I, Maamouri N, Mammi N, Saffar H, Trabelsi A, Triki H, Chouchane L.

J Med Virol. 2008 Apr;80(4):607-14. doi: 10.1002/jmv.21079.

PMID:
18297714
46.

Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81.

Zeisel MB, Koutsoudakis G, Schnober EK, Haberstroh A, Blum HE, Cosset FL, Wakita T, Jaeck D, Doffoel M, Royer C, Soulier E, Schvoerer E, Schuster C, Stoll-Keller F, Bartenschlager R, Pietschmann T, Barth H, Baumert TF.

Hepatology. 2007 Dec;46(6):1722-31.

47.

[Respiratory tract infections in institutions for elderly people: the GROG Géronto-Alsace, strategy of surveillance and alert].

Gaspard P, Mosnier A, Cohen JM, Gunther D, Quintle F, Eschbach E, Schwindenhammer R, Stoll-Keller F, Gayet S.

Med Mal Infect. 2007 Dec;37 Suppl 3:S215-22. Epub 2007 Nov 7. French.

PMID:
17997251
48.

Multicenter trials need to use the same assay for hepatitis C virus viral load determination.

Laperche S, Bouchardeau F, Thibault V, Pozzetto B, Vallet S, Rosenberg AR, Roque-Afonso AM, Gassin M, Stoll-Keller F, Trimoulet P, Gault E, Chanzy B, Mercier B, Branger M, Pawlotsky JM, Henquell C, Lunel F, Gaudy-Graffin C, Alain S, Chaix ML, Duverlie G, Izopet J, Lefrère JJ.

J Clin Microbiol. 2007 Nov;45(11):3788-90. Epub 2007 Oct 3.

49.

Neutralizing antibodies in hepatitis C virus infection.

Zeisel MB, Fafi-Kremer S, Fofana I, Barth H, Stoll-Keller F, Doffoel M, Baumert TF.

World J Gastroenterol. 2007 Sep 28;13(36):4824-30. Review.

50.

Early evolution of hepatitis C virus (HCV) quasispecies after liver transplant for HCV-related disease.

Schvoerer E, Soulier E, Royer C, Renaudin AC, Thumann C, Fafi-Kremer S, Brignon N, Doridot S, Meyer N, Pinson P, Ellero B, Woehl-Jaegle ML, Meyer C, Wolf P, Zachary P, Baumert T, Stoll-Keller F.

J Infect Dis. 2007 Aug 15;196(4):528-36. Epub 2007 Jun 29.

PMID:
17624837

Supplemental Content

Loading ...
Support Center